Genmab A/S
corporate_fare Company Profile
Genmab A/S (NASDAQ:GMAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for GMAB at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Genmab Files Comprehensive 2025 Annual Report, Details Merus Acquisition, $5.5B Debt, and 2026 Outlook
- Genmab Announces $14.35 Billion DARZALEX Net Sales for 2025
- Genmab's Epcoritamab Phase 3 Trial Shows Improved PFS in DLBCL, OS Misses Significance
Financial Snapshot
Insider Transactions
GMAB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.